CRIS Logo

Curis, Inc. (CRIS) 

NASDAQ
Market Cap
$34.06M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
500 of 775
Rank in Industry
269 of 433

Largest Insider Buys in Sector

CRIS Stock Price History Chart

CRIS Stock Performance

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, …

Insider Activity of Curis, Inc.

Over the last 12 months, insiders at Curis, Inc. have bought $0 and sold $0 worth of Curis, Inc. stock.

On average, over the past 5 years, insiders at Curis, Inc. have bought $0 and sold $28,729 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 25,000 shares for transaction amount of $24,500 was made by Rubin Marc (director) on 2017‑11‑16.

List of Insider Buy and Sell Transactions, Curis, Inc.

2022-01-31SalePresident & CEO
3,094
0.0032%
$3.07$9,499-70.22%
2022-01-27SalePresident & CEO
2,406
0.0027%
$3.18$7,651-68.40%
2021-01-26SalePresident & CEO
3,094
0.0036%
$10.59$32,758-21.62%
2021-01-25SalePresident & CEO
2,283
0.0027%
$10.96$25,022-23.56%
2020-01-24SalePresident & CEO
3,094
0.0087%
$1.64$5,076-29.41%
2020-01-23SalePresident & CEO
3,658
0.0109%
$1.69$6,182-27.27%
2019-01-24SalePresident & CEO
3,094
0.0082%
$1.16$3,577+36.36%
2019-01-23SalePresident & CEO
2,397
0.0074%
$1.09$2,613+68.22%
2019-01-23Saledirector
18,500
0.0549%
$1.05$19,477+68.22%
2019-01-23Saledirector
14,800
0.0439%
$1.05$15,587+68.22%
2019-01-23Saledirector
18,500
0.0549%
$1.05$19,475+68.22%
2019-01-23SaleHead of Research & Development
5,500
0.0166%
$1.07$5,900+68.22%
2019-01-23Saledirector
14,800
0.0439%
$1.05$15,581+68.22%
2017-11-16Purchasedirector
25,000
0.0176%
$0.98$24,500-46.99%
2017-11-15PurchasePresident & CEO
50,000
0.036%
$1.06$53,000-49.80%
2017-05-05Saledirector
16,176
0.0113%
$1.90$30,721-20.63%
2017-05-04Saledirector
30,100
0.0213%
$1.97$59,159-22.42%
2017-05-03Saledirector
30,000
0.0213%
$2.18$65,544-29.21%
2017-05-02Saledirector
35,646
0.0249%
$2.31$82,314-33.48%
2017-05-01Saledirector
38,113
0.0266%
$2.38$90,709-34.81%

Insider Historical Profitability

4.29%
Aurigene Discovery Technologies Ltd10 percent owner
27328464
322.766%
$4.0210+38.59%
PASSERI DANIEL Rdirector
198898
2.3491%
$4.02231<0.0001%
Fattaey Ali Ph.D.President & CEO
115890
1.3687%
$4.0230<0.0001%
GRAY MICHAELCFO
107304
1.2673%
$4.0216<0.0001%
MCNAB JAMES Rdirector
50000
0.5905%
$4.02929+15.48%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Maverick Capital Ltd$6.33M9.88582,2730%+$00.12
M28 Capital Management Lp$4.59M7.16421,9510%+$03.39
Kingdon Capital Management$3.09M4.82284,1500%+$00.41
The Vanguard Group$2.38M3.71218,573+4.84%+$109,754.41<0.0001
Cm Management Llc$1.3M2.04120,000+380%+$1.03M0.03
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.